How the advent of anti-VEGF has completely reshaped management of DME. This month’s feature takes a look at the DRCR.net trials—and an overview of new treatments in the pipeline.
The March supplement from MedEdicus can be found here: Improving Treatment Burden and Outcomes for Patients With Neovascular Age-Related Macular Degeneration Now and Into the Future.
Does your practice have a MIPS point person? Make sure they have access to EyeNet’s MIPS 2020: A Primer and Reference, which is posted online ahead of print.
Public & Patients